Previous Close | 0.1700 |
Open | 0.1689 |
Bid | 0.1700 x 100 |
Ask | 0.1750 x 200 |
Day's Range | 0.1680 - 0.1900 |
52 Week Range | 0.1400 - 1.6000 |
Volume | |
Avg. Volume | 519,767 |
Market Cap | 7.121M |
Beta (5Y Monthly) | -0.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for NLSP
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ...
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for ...
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological therapies. Medications activating dual OX1R/OX2R ...